Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-

Satsuma Pharmaceuticals Announces Updated STS101 Development Plan

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional details below:

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference 

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company focused on developing STS101 (a dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical development and corporate update.

Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

- Credit Suisse - 29th Annual Healthcare Conference - November 9 th -1 2 th

Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences

Satsuma Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Satsuma Pharmaceuticals Enters Oversold Territory

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

Satsuma Plunges on Disappointing Data on Migraine Treatment

Investors are reeling from a late-stage flop for the company's only pipeline candidate.

Why Satsuma Pharmaceuticals Stock Is Plummeting Today

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) has reported disappointing late-stage results from its migraine treatment, and its shares were absolutely crushed Thursday morning.

This Late-Stage Study Is Giving Satsuma Pharma Stock Migraines

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the following conferences in the month of September:

Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business progress  and reported financial results for the second quarter ended June 30, 2020.

Satsuma Pharmaceuticals Provides Business Update and Reports  Second Quarter 2020 Financial Results

ASCEND results expected to support STS101 NDA filing in Q4 2021

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101

SOUTH SAN FRANCISCO, Calif., July  07, 2020  (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry veteran Thomas M. Soloway to its Board of Directors effective July 2, 2020.  Mr. Soloway currently serves as Executive Vice President and Chief Operating Officer of Audentes Therapeutics Inc., an Astellas genetic medicines company committed to developing and commercializing innovative gene therapy products for patients living with rare, life-threatening diseases.

Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting Platform

More than 1,140 patients randomized and topline results expected in second half 2020 More than 1,140 patients randomized and topline results expected in second half 2020

Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data  expected in second half of 2020

Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results

Akebia Therapeutics

Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.

2 Small-Cap Stocks That Could Double Your Money

SOUTH SAN FRANCISCO, Calif., March  05, 2020  (GLOBE NEWSWIRE) --  Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob Janosky to the newly created position of Chief Commercial Officer.  As Satsuma’s Chief Commercial Officer, Mr. Janosky will be responsible for all commercial activities, as well as leading business development and corporate partnering.

Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Feb.  18, 2020  (GLOBE NEWSWIRE) --  Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020 in New York City.

Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan.  28, 2020  (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safety with its lead product candidate, STS101 (DHE (or dihydroergotamine) nasal powder for the acute treatment of migraine), have been published online in the official peer-reviewed journal of the American Headache Society, Headache, The Journal of Head and Face Pain.

Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain

SOUTH SAN FRANCISCO, Calif., Nov.  26, 2019  (GLOBE NEWSWIRE) --  Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma President and Chief Executive Officer, will present a corporate update at the Evercore ISI HealthCONx Investor Conference, taking place December 3-5, 2019 in Boston.

Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

Satsuma Pharma (NASDAQ: STSA) made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per share.

News for Satsuma Pharmaceuticals Inc Stock (STSA)